Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
The administration of the immunosuppressive humanized monoclonal antibody CAMPATH 1-H, which recognizes CD52 on lymphocytes and monocytes, is associated with a first-dose cytokine-release syndrome involving TNFalpha, IFNgamma, and IL-6 clinically. In vitro models have been used to establish the cell...
Auteurs principaux: | Wing, MG, Moreau, T, Greenwood, J, Smith, R, Hale, G, Isaacs, J, Waldmann, H, Lachmann, P, Compston, A |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
1996
|
Documents similaires
-
Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
par: Williams, R, et autres
Publié: (2000) -
Tolerance induction in the adult using monoclonal antibodies to CD4, CD8, and CD11a (LFA-1).
par: Waldmann, H, et autres
Publié: (1989) -
TOLERANCE INDUCTION IN THE ADULT USING MONOCLONAL-ANTIBODIES TO CD4, CD8, AND CD11A (LFA-1)
par: Waldmann, H, et autres
Publié: (1989) -
Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa.
par: Cooke, G, et autres
Publié: (2003) -
CAMPATH-1H in inflammatory arthritis.
par: Watts, R, et autres
Publié: (1993)